All In Biotech

Drug Trial Radar · NCT01125800

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma

Last checked: Nov 19, 2026Latest source record: Mar 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

76

Actual

Start

Feb 2011

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 18, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other tumors potentially dependent on Hedgehog signaling pathway. Phase II study is to assess preliminary efficacy in both adult and pediatric patients with recurrent or refractory MB.

Conditions

  • Medulloblastoma
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Hepatoblastoma
  • Glioma
  • Astrocytoma

Interventions

  • LDE225Drug

    LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting Toxicities (DLT) in Phase ITime frame: Baseline, End of dose escalation part (Day 42)
  2. Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged UseTime frame: Baseline, End of dose escalation part (Day 42)
  3. Percentage of Participants With Objective Response Rate (ORR) by TreatmentTime frame: Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • Children's Healthcare of Atlanta Childern Hosp - ATL

    Atlanta, Georgia

  • Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins

    Baltimore, Maryland

  • Dana Farber Cancer Institute DFCI (3)

    Boston, Massachusetts

  • Seattle Children's Hospital CPKC412A2114

    Seattle, Washington

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Newcastle upon Tyne, United Kingdom

  • Novartis Investigative Site

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.